LEO Pharma and ICON have announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective. The mission of the partnership is to improve the lives of dermatology patients with access to innovative clinical trials and the launch of new medicines.
The partnership will leverage both fully outsourced and functional outsourcing models in a hybrid approach. In supporting LEO Pharma through this partnership, ICON will draw upon a team from across its business to deliver tailored solutions, bringing capabilities including its laboratories, Accellacare site-network, FIRECREST site management, and DCT capabilities.
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology. (2023, March 10). Business Wire.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.